1009P Integrated biomarker analysis of brigatinib efficacy in anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) refractory to alectinib
| Autor: | Ou, S-H.I., Nishio, M., Yoshida, T., Ahn, M-J., Mok, T.S.K., Kudou, K., Asato, T., Yang, H., Tong, X., Zhang, P., Yamamoto, N., Kim, E.S. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S1014-S1015 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|